April 25 (Reuters) - Crescita Therapeutics Inc CTX.TO
* Crescita Therapeutics announces agreement with Taro Pharmaceuticals for Pliaglis
* Crescita Therapeutics - entered development and commercialization license agreement with Taro Pharmaceuticals, unit of Taro Pharmaceutical Industries
* Crescita Therapeutics - under terms of agreement, Crescita has granted Taro exclusive license to rights to sell and distribute Pliaglis in U.S. market
* Crescita Therapeutics Inc - in consideration of rights granted under agreement taro will make an upfront, non-dilutive payment of US$2.0 million to Crescita
* Crescita Therapeutics Inc - under deal Taro will also make up to US$5.75 million in non-dilutive development and sales milestone payments to Crescita
* Crescita Therapeutics Inc - in addition, Crescita and Taro have entered into a fee-for-service development agreement
* Crescita Therapeutics Inc - Crescita retains all rights to Pliaglis in Canada and Mexico
* Crescita Therapeutics Inc - fee-for-service development with Taro wherein co to provide services related to development of Pliaglis and enhanced formulation
* Crescita Therapeutics Inc - co to receive fees related to fee-for service development based on services performed Source text for Eikon: ID:nPn6k6W21a Further company coverage: CTX.TO